Jerry Jaboin is an Oncology physician affiliated with Oklahoma State University Oklahoma City. OpenAlex indexes 217 publications with 3,471 citations (h-index 29); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 NE 10th St # Okccl100
Oklahoma City, OK 731045418
Telephone
405-271-5641Provider last certified this registry record 30 Mar 2023.
Clinical trials
- Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy
Sponsor: OHSU Knight Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- icotec Medical Inc.Program year20252 payments
- HISTOSONICS, INC.Program year20251 payment
- Siemens Medical Solutions USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
47.2%Corticosteroid47.2%Dexamethasone100%Part D≥15 patientsMetabolism & gastrointestinal
32.1%Proton pump inhibitor32.1%Omeprazole100%Part D<11 patientsNervous system
20.8%Benzodiazepine20.8%Lorazepam100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tumor Microenvironment Dynamics of Triple-Negative Breast Cancer Under Radiation Therapy
International Journal of Molecular Sciences
2025 - An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
CA A Cancer Journal for Clinicians
2022 - Navigator-assisted hypofractionation (NAVAH) to address radiation therapy access disparities facing African-Americans with breast cancer
Reports of Practical Oncology & Radiotherapy
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Courtney Houchen, MD
Oklahoma State University Oklahoma City
Hassan Hatoum, MD
Oklahoma State University Oklahoma City
Wajeeha Razaq, MD
Oklahoma State University Oklahoma City
Manu Pandey, MD
Oklahoma State University Oklahoma City
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”